Nextbiomedical Co. Ltd. 389650
KRX · South Korea · Health Technology
KRW 31,750.00-1,450.00 (-4.37%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
NEXTBIOMEDICAL, a medical device company specializing in innovative therapeutic solutions, participated in CIRSE 2026, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held in Copenhagen, Denmark, from September 5 to 9. The company operated an exhibition booth and a large-scale Learning Center showcasing its embolic agents, Nexsphere™ and Nexsphere-F™.
NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Radiology, the leading peer-reviewed journal in radiology and medical imaging with an impact factor of 17.6, has published clinical results for Nexsphere-F™, the Company's fast-resorbable microsphere for embolization.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.